logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO 2018—Pembrolizumab disappoints in KEYNOTE-061 trial for advanced/metastatic gastric or gastroesophageal junction cancer

Some patients may benefit, however.